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Abstract
Background: In comparison to the well established changes in compliance that occur at the large
vessel level in diabetes, much less is known about the changes in compliance of the cardiovascular
system at the end-organ level. The aim of this study was therefore to examine whether there was
a correlation between resistance of the intrarenal arteries of the kidney and compliance of the left
ventricle, as estimated by measurements of diastolic function, in subjects with type 2 diabetes.
Methods: We studied 167 unselected clinic patients with type 2 diabetes with a kidney duplex scan
to estimate intrarenal vascular resistance, i.e. the resistance index (RI = peak systolic velocity-
minimum diastolic velocity/peak systolic velocity) and a transthoracic echocardiogram (TTE)
employing tissue doppler studies to document diastolic and systolic ventricular function.
Results: Renal RI was significantly higher in subjects with diastolic dysfunction (0.72 ± 0.05) when
compared with those who had a normal TTE examination (0.66 ± 0.06, p < 0.01). Renal RI values
were correlated with markers of diastolic dysfunction including the E/Vp ratio (r = 0.41, p < 0.001),
left atrial area (r = 0.36, p < 0.001), the E/A ratio (r = 0.36, p < 0.001) and the E/E' ratio (r = 0.31,
p < 0.001). These associations were independent of systolic function, hypertension, the presence
and severity of chronic kidney disease, the use of renin-angiotensin inhibitors and other potentially
confounding variables.
Conclusion: Increasing vascular resistance of the intrarenal arteries was associated with markers
of diastolic dysfunction in subjects with type 2 diabetes. These findings are consistent with the
hypothesis that vascular and cardiac stiffening in diabetes are manifestations of common
pathophysiological mechanisms.
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Background
Diabetes is associated with the premature development of
large vessel arterial stiffness [1]. Increased arterial stiffness
is known to be associated with cardiac and kidney dys-
function and is a powerful risk factor for early mortality
[2]. In comparison to the well-established changes in
compliance that occur at the large vessel level in diabetes,
much less is known about the changes in compliance of
the cardiovascular system at the end-organ level.
Early in the course of diabetes, progressive cardiac fibrosis
and hypertrophy lead impaired relaxation and a stiff left
ventricle. We have previously found 'diastolic dysfunc-
tion' in over half of all unselected patients with type 2 dia-
betes attending a diabetes clinic at a tertiary care center
[3,4]. Furthermore, recent epidemiological studies show
that diastolic dysfunction is an independent risk factor for
cardiac death [5]. We have also shown that increased
resistance of the intrarenal arteries is associated with a
reduced glomerular filtration rate (GFR), an independent
predictor of cardiac mortality [6-8].
These findings led us to hypothesize that reduced compli-
ance of the intrarenal arteries that is associated with dia-
betic kidney disease, is mirrored by changes in the
diabetic heart, which are manifested by worsening mark-
ers of diastolic function. The aim of this study was there-
fore to search for a link between compliance of the
intrarenal arteries and compliance of the left ventricular
wall in individuals with type 2 diabetes.
Methods
Subjects
We studied 167 unselected patients with type 2 diabetes
attending the diabetes clinics at the Endocrine Centre,
Austin Health, Australia. The Austin Health Human
Research Ethics Committee approved the research
described in this study and informed consent was
obtained from all participants.
Kidney duplex scans
Intra-renal vascular resistance was estimated by renal
duplex ultrasound as previously described [6]. The renal
resistance index (RI) was calculated as the peak systolic
velocity – end diastolic velocity)/peak systolic velocity.
The upper end of the normal range for intra-renal RI val-
ues in healthy subjects is < 0.7 [9]. Individuals with an RI
> 0.7 were said to have increased intra-renal vascular
resistance
Transthoracic echocardiograms
Transthoracic echocardiogram (TTE) was performed using
a commercially available ultrasound system (Acuson
Sequoia, 3.5 Mhz transducer) in the left lateral decubitus
position and methods that have been described previ-
ously [3,4]. Recordings and measurements were obtained
according to the published recommendations of the
American Society of Echocardiography [10,11] and ana-
lysed by two experienced, independent observers. Con-
ventional parameters of diastolic function were measured
at the mitral leaflet tips over three consecutive cardiac
cycles. In the apical four chamber view, a 2 mm pulse
wave Doppler sample gate was placed at the medial mitral
annulus to obtain the peak early diastolic (E'), and used
to calculate the E/E' ratio. Diastolic function was classified
according to the Canadian consensus on diastolic dys-
function [12]. Systolic dysfunction was defined by evi-
dence of regional wall motion abnormalities and/or an
ejection fraction of less than 50%.
Clinical and biochemical measurements
An isotopic glomerular filtration rate (iGFR) was meas-
ured by the plasma disappearance of isotopic 99mTc-dieth-
ylene-triamine-penta-acetic acid (DTPA) employing the
Brochner-Mortensen correction. Glycated haemoglobin
(HbA1c), fasting lipids, serum electrolytes and urinary
albumin excretion (AER) were measured as previously
described [6,13]. A full clinical and medication history
including the presence or absence of diabetic and cardio-
vascular complications, and treatment history was also
recorded for each participant.
Statistics
Continuous data are expressed as mean ± standard devia-
tion (SD). Categorical data are expressed as frequency
(%). Where appropriate, means and proportions were
compared by using analysis of variance and chi-square
tests, respectively. The Pearson method was used to test
for a correlation between the intrarenal RI and the
echocardiographic parameters of diastolic function. A
multivariate linear regression model was used to confirm
the contribution of independent association between RI
and cardiac parameters. All variables known to be associ-
ated with diastolic function were included in the final
model, along with any variables associated with diastolic
function in univariate analyses with a p value < 0.01. The
potential for multiple colinearity was tested using the var-
iance inflation factor (VIF) and condition number (CN),
where VIF <10 and CN <30 are desirable.
Results
The clinical and biochemical characteristics of the study
population are shown in Table 1. Many clinic subjects
were obese (57%), had hypertension (81%) or estab-
lished cardiovascular disease (36%). Over half of all
patients in this cohort had chronic kidney disease (CKD)
including elevated AER levels (>20 μg/min) in 45% and
22% with an iGFR < 60 ml/mim/1.73 m2.Cardiovascular Diabetology 2008, 7:15 http://www.cardiab.com/content/7/1/15
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Subjects were further stratified according to results of their
TTE examination. Thirty five percent of participants had
normal cardiac function on TTE examination (n = 59).
However, the majority of diabetic subjects (65%) had
abnormal cardiac function (n = 108), including 66 indi-
viduals with diastolic dysfunction alone (40%), 30 with
concurrent diastolic and systolic dysfunction (18%) and
in a small number of individuals (n = 12) isolated systolic
dysfunction was the only finding (7%). Subjects with
diastolic dysfunction were generally older, had a greater
frequency of hypertension and renal impairment than
those with a normal TTE examination. As expected, sub-
jects with concurrent systolic dysfunction had a greater
prevalence of past CVD (Table 1).
The mean renal RI was 0.69 ± 0.01 in the total cohort with
48% of subjects with type 2 diabetes having an elevated RI
beyond the normal range (> 0.7). As shown in Figure 1,
renal RI values were significantly higher in with (any)
diastolic dysfunction (0.72 ± 0.06) compared with those
who had a normal TTE examination (0.66 ± 0.06, p <
0.01). Moreover, the finding of an elevated RI level (> 0.7)
was twice as common in individuals with (any) diastolic
dysfunction compared with those who had a normal TTE
examination (59% vs 25%, p < 0.001). Less than 18% of
all those with elevated RI levels (> 0.7) in this cohort had
normal cardiac function. As shown in Table 1, RI levels
were elevated to a similar extent in subjects with diastolic
dysfunction alone (0.72 ± 0.06) and in those with concur-
rent diastolic and systolic dysfunction (0.71 ± 0.06) when
compared those who had a normal TTE examination
(0.66 ± 0.06, both p < 0.01).
As shown in figure 2, renal RI values were correlated with
markers of diastolic dysfunction including the E/Vp ratio
(r = 0.41, p < 0.001) and left atrial area (r = 0.36, p <
0.001). Renal RI values were also associated with the E/A
ratio (r = 0.36, p < 0.001) and the E/E' ratio (r = 0.31, p <
0.001). The association between renal RI levels and all of
the above markers of diastolic dysfunction remained sig-
nificant (all p <0.001) after correcting for multiple clinical
and biochemical variables including age, duration of dia-
betes, BMI, blood pressure, albumin excretion rate, iGFR
levels, use of blockers of the renin-angiotensin system, as
well as adjusting for parameters of systolic function.
While renal RI values were weakly correlated with param-
eters of systolic function (e.g fractional shortening and
ejection fraction, both p = 0.05), these associations were
eliminated after adjusting for age.
Table 1: Clinical and biochemical parameters for 167 subjects with type 2 diabetes, stratified according to cardiac function
Total cohort (n = 167) Normal cardiac 
function (n = 59)
Diastolic dysfunction alone 
(n = 66)
Diastolic and systolic 
dysfunction (n = 30)
Intrarenal RI 0.69 ± 0.01 0.66 ± 0.06 0.72 ± 0.06** 0.71 ± 0.06**
Age (years) 62 ± 12 55 ± 13 66 ± 9* 66 ± 12*
Sex (% male) 59% 59% 54% 72%
Diabetes duration (years) 11 ± 8 9 ± 6 13 ± 8* 10 ± 7
Obese BMI (>30 kg/m2, %) 57% 48% 60% 56%
History of CVD (%) 36% 23% 32% 69%*
HbA1c (%) 7.7 ± 1.5 8.1 ± 1.5 7.6 ± 1.3* 7.4 ± 1.9*
Metformin use(%) 68% 80% 55%* 69%
Sulphonylurea use (%) 57% 62% 50% 72%
Glitazone use (%) 19% 31% 11%* 17%
Insulin use (%) 42% 45% 46% 24%
Hypertension (%) 81% 69% 85%* 90%*
Systolic BP (mmHg) 140 ± 17 135 ± 17 144 ± 18 141 ± 15
Diastolic BP (mmHg) 75 ± 8 76 ± 8 74 ± 8 76 ± 9
RAS inhibitor use (%) 72% 54% 84%* 83%*
Number of 
antihypertensives (n)
1.9 ± 1.4 1.3 ± 1.3 2.1 ± 1.4* 2.7 ± 1.5*
Total cholesterol (mM) 4.7 ± 0.9 4.9 ± 1.0 4.8 ± 0.8 4.6 ± 1.0
Triglycerides (mM) 2.1 ± 1.2 2.3 ± 1.3 2.0 ± 1.1 2.3 ± 1.4
Treatment for dyslipidaemia 63% 58% 53% 90%*
History of retinopathy 27% 14% 44%* 17%
iGFR (ml/min/1.73 m2) 93 ± 32 111 ± 27 82 ± 27* 73 ± 30*
GFR< 60 (ml/min/1.73 m2) 22% 6% 25%* 39%*
AER > 20 (μg/min) 45% 41% 39% 59%*
Data for continuous variables are mean ± SD. Data for categorical variables are expressed as proportions.
* p < 0.05, ** p < 0.01 vs individuals with normal cardiac function on TTE,Cardiovascular Diabetology 2008, 7:15 http://www.cardiab.com/content/7/1/15
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Discussion
This study shows that resistance of the intrarenal arteries
is closely linked with abnormal cardiac function in
patients with type 2 diabetes. In particular, there was a
continuous relationship between increasing resistance of
the intrarenal arteries and established indices of left ven-
tricular filling pressure and diastolic function. These asso-
ciations were independent of systolic function,
hypertension, the presence and severity of chronic kidney
disease, the use of renin-angiotensin inhibitors and other
potentially confounding variables.
These data support the hypothesis of a common pathway
to diabetic complications, which promotes stiffening and
progressive dysfunction in both the heart and major ves-
sels. Such common contributory factors may include oxi-
dative stress, insulin resistance, inflammation, the
accumulation of advanced glycation end products
(AGEs), activation of the rennin angiotensin system
(RAS), arterial calcification and endothelial (dys)func-
tion. However, it is likely that a parallel increase in the
resistance of the intrarenal arteries and indices of diastolic
dysfunction also partly reflects a generalized reduction in
vascular compliance associated with arteriosclerosis in a
range of vascular beds. In support of this suggestion, both
the intra-renal RI and parameters of diastolic dysfunction
have been shown to be associated with systemic pulse
wave velocity, arterial compliance, and systemic vascular
damage in both diabetic and non-diabetic subjects
[14,15].
Limitations
One of the weaknesses of this study was that we did not
measure total arterial compliance and that we have used
the intrarenal RI and indices of diastolic dysfunction as
surrogate markers of intrarenal arterial and ventricular
compliance, respectively. It is appreciated that functional
as well as structural parameters may have influenced our
results. Also, we did not account for the possibility of the
presence of an elevated central venous pressure or auto-
nomic neuropathy, factors that may have contributed to
the development of both intrarenal arterial compliance
and diastolic dysfunction.
Conclusion
This study demonstrates that worsening indices of diasto-
lic function in subjects with type 2 diabetes parallels
increases in resistance of the intrarenal vessels. These find-
ings are consistent with the hypothesis that both the
development of vascular and myocardial stiffening in dia-
betes are manifestations of common pathophysiological
mechanisms. It is possible that these processes also con-
tribute to the link between renal dysfunction and cardio-
vascular outcomes in subjects with type 2 diabetes [7,8].
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Intrarenal resistance index values in subjects with type 2 dia- betes, stratified according to cardiac function on a transtho- racic echocardiogram Figure 1
Intrarenal resistance index values in subjects with 
type 2 diabetes, stratified according to cardiac func-
tion on a transthoracic echocardiogram.   denotes indi-
viduals with normal cardiac function.  denotes individuals 
with diastolic dysfunction alone. ♦ denotes individuals with 
diastolic and systolic dysfunction. ** P < 0.01 vs normal tran-
sthoracic echocardiogram.Cardiovascular Diabetology 2008, 7:15 http://www.cardiab.com/content/7/1/15
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Correlations between the intrarenal resistance index and markers of diastolic dysfunction, i.e., (A) the E/Vp ratio (r = 0.41, p <  0.001) and (B) left atrial area (r = 0.36, p < 0.001) Figure 2
Correlations between the intrarenal resistance index and markers of diastolic dysfunction, i.e., (A) the E/Vp ratio (r = 0.41, p < 
0.001) and (B) left atrial area (r = 0.36, p < 0.001). Solid lines denote the linear regression relationship between the variables. 
The dotted lines denote the 95% confidence interval for the regression relationship.
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